Abstract
Plasmodium falciparum is the most serious health threat in Sub-Saharan Africa1. This situation is further aggravated by the resistance to currently known antimalarials coupled with the lack of an effective vaccine. Therefore, there is an urgent need to discover new viable biochemical targets and biologically active compounds. The discovery of a type II fatty acid biosynthesis pathway (FAS II) in P. falciparum, particularly, the enoyl-ACP reductase (PfENR), which catalyses the rate limiting step in each elongation circle, has been recognized and validated as an important target2,3. The present work capitalizes on the discovery of new antimalarial molecules based on PfENR inhibition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
